Effect of Empagliflozin and Colesevelam on Diabetic Dyslipidemia
Effect of Empagliflozin and its combination with Colesevelam on experimentally induced diabetic dyslipidemia animals
Versandkostenfrei!
Versandfertig in 6-10 Tagen
29,99 €
inkl. MwSt.
PAYBACK Punkte
15 °P sammeln!
Diabetes Mellitus (DM) is a persistent metabolic cluster of diseases that involves erroneously excessive blood glucose levels and relative comorbidities. Dyslipidemia is one of the primarily occurred complications in Diabetic (DM) patients. This experimental study is aimed at investigating the effect of combination therapy of Empagliflozin + Colesevelam in Diabetic Dyslipidemia rats. Total number of 30 Albino Wistar rats were used for this study and HbA1C, Fasting Blood Glucose (FBG) like diabetic and HDL-c, LDL-c, TGs, Total Cholesterol (TC) like lipid parameters were estimated. Renal profile...
Diabetes Mellitus (DM) is a persistent metabolic cluster of diseases that involves erroneously excessive blood glucose levels and relative comorbidities. Dyslipidemia is one of the primarily occurred complications in Diabetic (DM) patients. This experimental study is aimed at investigating the effect of combination therapy of Empagliflozin + Colesevelam in Diabetic Dyslipidemia rats. Total number of 30 Albino Wistar rats were used for this study and HbA1C, Fasting Blood Glucose (FBG) like diabetic and HDL-c, LDL-c, TGs, Total Cholesterol (TC) like lipid parameters were estimated. Renal profile was evaluated by investigating animals for serum creatinine and Urinary albumin. Animals of the EMPA + BAS shows the decrease in Diabetic, Lipid and renal parameters than other groups. This study showed that Dyslipidemia is highly prevalent among TIIDM induced animals and combination of EMPA + BAS can be proven better therapy for Diabetic Dyslipidemia.
Andere Kunden interessierten sich für
